TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32741045

Group type: EXPERIMENTAL
Intervention: Youth-directed goal setting incorporating blood glucose monitoring (BGM), continuous glucose monitoring (CGM), and insulin dosing
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sessions where goal intentions focused on BG only (without addressing insulin or CGM)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sessions where goal intentions focused on insulin dosing only (without addressing BGM or CGM)
Number of subjects: 122
Study: 32741616

Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) in KIR AA mothers
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) in KIR AB mothers
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) in KIR BB mothers
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Double embryo transfer (DET) with oocyte donation in KIR AA patients
Number of subjects: 204

Group type: COMPARATOR
Intervention: Elective single embryo transfer (SET)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Increased embryo HLA-C2 load in KIR AA patients
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Selection of HLA-C1 over HLA-C2 donors
Number of subjects: 204
Study: 32741971

Group type: EXPERIMENTAL
Intervention: LY3127804 monotherapy (4, 8, 12, 16, 20 and 27 mg/kg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: LY3127804 (8, 12, 16, 20 and 27 mg/kg) with 8 mg/kg ramucirumab
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: LY3127804 (20 mg/kg) with 12 mg/kg ramucirumab
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination therapy (LY3127804 with ramucirumab)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: LY3127804 20 mg/kg
Number of subjects: 62
Study: 32742241

Group type: EXPERIMENTAL
Intervention: Biotin-labeled molecular probes comprising specific regions of the SARS-CoV-2 spike; yields from transient transfection ranged from ~0.5 mg/L for the complete ectodomain to >5 mg/L for several subregions.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Biotinylated probes; characterized for antibody-binding specificities and cell-sorting capabilities.
Number of subjects: 2
Study: 32742443

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with oral etoposide and cisplatin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 68
Study: 32742711

Group type: EXPERIMENTAL
Intervention: Biosimilar recombinant follicle stimulating hormone (rFSH)
Number of subjects: 1222
Study: 32743009

Group type: EXPERIMENTAL
Intervention: Forced spirometry
Number of subjects: 1988

Group type: COMPARATOR
Intervention: Body plethysmography
Number of subjects: 1988
Study: 32743011

Group type: EXPERIMENTAL
Intervention: Intra-articular administration of Tranexamic Acid (TXA) 100 mL (30 mg/mL)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no IA injection of TXA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intra-articular administration of Tranexamic Acid (TXA)
Number of subjects: 47
Study: 32743079

Group type: EXPERIMENTAL
Intervention: PS/EF CCT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Verbal CCT
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90
Study: 32743692

Group type: EXPERIMENTAL
Intervention: Smartphone-based self-monitored mood
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Smartphone-based self-monitored activity
Number of subjects: 206
Study: 32743756

Group type: EXPERIMENTAL
Intervention: UKA with patella denervation (PD)
Number of subjects: 66

Group type: COMPARATOR
Intervention: UKA without patella denervation (no-PD)
Number of subjects: 66
Study: 32743852

Group type: EXPERIMENTAL
Intervention: Antithrombotics
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drugs
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Antihypertensives
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Antidiabetic drugs
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Medication adherence (self-reported)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Blood pressure control
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: LDL-C control
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: HbA1c control (for diabetic patients)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 664

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 664
Study: 32744105

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Lipid-lowering treatment in patients with definite/probable FH
Number of subjects: 367
Study: 32745296

Group type: EXPERIMENTAL
Intervention: Community stigma
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: Internalised stigma
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: Poor ART adherence
Number of subjects: 1888

Group type: EXPERIMENTAL
Intervention: Health setting stigma
Number of subjects: 1888
Study: 32745512

Group type: EXPERIMENTAL
Intervention: Front-line health-care workers
Number of subjects: 2135190

Group type: COMPARATOR
Intervention: General community
Number of subjects: 2135190
Study: 32745961

Group type: EXPERIMENTAL
Intervention: ssCART-19s (CAR-T therapy targeting CD19 with shRNA-IL-6 gene silencing)
Number of subjects: 3
Study: 32746802

Group type: EXPERIMENTAL
Intervention: PartoSure® test
Number of subjects: 400
Study: 32746820

Group type: EXPERIMENTAL
Intervention: GERD
Number of subjects: 5728
Study: 32746839

Group type: EXPERIMENTAL
Intervention: ppRx with immunotherapy or targeted therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other treatments after progression
Number of subjects: 0
Study: 32746884

Group type: EXPERIMENTAL
Intervention: Before the discovery of the causal mutation in 1996
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: After the introduction of genetic testing in 1996
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Patients with non-neurological presentation after 1996
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Patients with neurological presentation after 1996
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Patients with late-onset FRDA
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Patients with typical onset (age < 25 years)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Correlation of age at onset with GAA repeat length (GAA1) in neurological onset cases
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Correlation of age at onset with GAA repeat length (GAA1) in non-neurological presentation
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Differences in age at onset among 54 siblings' pairs
Number of subjects: 611
Study: 32746893

Group type: EXPERIMENTAL
Intervention: Wearable activity trackers (Fitbit Charge HR2) during weeks with gout flares
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wearable activity trackers (Fitbit Charge HR2) during non-flare periods
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Wearable activity trackers (Fitbit Charge HR2)
Number of subjects: 44
Study: 32747077

Group type: EXPERIMENTAL
Intervention: Isoflurane general anaesthesia
Number of subjects: 589
Study: 32747075

Group type: EXPERIMENTAL
Intervention: Prehospital intubation
Number of subjects: 4509

Group type: EXPERIMENTAL
Intervention: In-hospital intubation
Number of subjects: 4509
Study: 32747205

Group type: EXPERIMENTAL
Intervention: nutritionDay 2.0 audit and feedback intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nutritionDay 2.0 tools
Number of subjects: 0
Study: 32747357

Group type: EXPERIMENTAL
Intervention: cAMB administered at 1.0 g per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cAMB administered at 1.5 g per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cAMB administered at 2.0 g per day
Number of subjects: 0
Study: 32747469

Group type: EXPERIMENTAL
Intervention: T-cell therapy (tumor-infiltrating lymphocytes, TILs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous progression on anti-CTLA-4 therapy
Number of subjects: 0
Study: 32747693

Group type: EXPERIMENTAL
Intervention: Ayton risk tool
Number of subjects: 971

Group type: COMPARATOR
Intervention: Balkus risk tool
Number of subjects: 971
Study: 32747953

Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation (PPI)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) at discharge
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Postoperative AF
Number of subjects: 704
Study: 32748394

Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure (BP)
Number of subjects: 536607

Group type: COMPARATOR
Intervention: Korotkoff phase IV (K4) technique for diastolic BP measurement
Number of subjects: 536607

Group type: COMPARATOR
Intervention: CRADLE device (semi-automated BP monitor)
Number of subjects: 536607
Study: 32748658

Group type: EXPERIMENTAL
Intervention: Daily activity energy expenditure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity duration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Light activity time
Number of subjects: 20
Study: 32748666

Group type: EXPERIMENTAL
Intervention: Cognitive augmented mobility program (CAMP)
Number of subjects: 0
Study: 32748789

Group type: EXPERIMENTAL
Intervention: Evolut PRO transcatheter heart valve (23, 26, or 29 mm)
Number of subjects: 629
Study: 32749224

Group type: EXPERIMENTAL
Intervention: Web-based positive psychological intervention (¡Alégrate!) for 5 weeks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active control condition (3 times weekly emotion reporting).
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Web-based positive psychological intervention (¡Alégrate!).
Number of subjects: 70
Study: 32749710

Group type: EXPERIMENTAL
Intervention: DAA treatment (direct-acting antivirals)
Number of subjects: 2167
Study: 32749716

Group type: EXPERIMENTAL
Intervention: Retrospective natural history study
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Retrospective deep phenotyping and detailed variant analysis
Number of subjects: 35
Study: 32749995

Group type: EXPERIMENTAL
Intervention: More Stamina mobile app for fatigue self-management
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study: 32749998

Group type: EXPERIMENTAL
Intervention: Digital mental health intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32750120

Group type: EXPERIMENTAL
Intervention: Influenza positive defined as positive PCR or seroconversion against influenza A with no vaccination record during follow-up.
Number of subjects: 289
Study: 32750290

Group type: EXPERIMENTAL
Intervention: Decreased HRV index ≤ median (14.29)
Number of subjects: 1922

Group type: COMPARATOR
Intervention: Standard HRV parameters (HRV triangular index, SD of normal-to-normal intervals, square root of mean squared differences of successive normal-to-normal intervals, mean heart rate)
Number of subjects: 1922
Study: 32750295

Group type: EXPERIMENTAL
Intervention: Serum Ec-SOD activity in patients with normal LV geometry
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Serum Ec-SOD activity in patients with abnormal LV geometry without HF
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Serum Ec-SOD activity in patients with abnormal LV geometry and overt HF
Number of subjects: 1047
Study: 32750311

Group type: EXPERIMENTAL
Intervention: Children born preterm
Number of subjects: 126
Study: 32750486

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HFpEF with diabetes
Number of subjects: 121

Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 121
Study: 32750501

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy without pelvic lymph node dissection
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: SLN frozen section assessment
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: SLN biopsy
Number of subjects: 395
Study: 32751415

Group type: EXPERIMENTAL
Intervention: Mastiha Oil
Number of subjects: 0
Study: 32753377

Group type: EXPERIMENTAL
Intervention: High-risk group (RR, 2.0-4.6)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal-risk group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High-risk group (Ductal endoscopy)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Normal-risk group (Ductal endoscopy)
Number of subjects: 140
Study: 32753395

Group type: EXPERIMENTAL
Intervention: HEAR Pathway risk assessments (HEAR scores and serial troponin testing at 0 and 3 hours)
Number of subjects: 4979
Study: 32753397

Group type: EXPERIMENTAL
Intervention: Sialidosis type I patients
Number of subjects: 7
Study: 32753543

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitor therapy (CIT)
Number of subjects: 0
Study: 32753546

Group type: EXPERIMENTAL
Intervention: CC-486 300 mg QD Days 1-14 (cycles 1-3 only) + durvalumab 1500 mg IV day 15 (regimen A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: CC-486 100 mg QD days 1-21 + vitamin C 500 mg once a day continuously + durvalumab 1500 mg IV day 15 (regimen B)
Number of subjects: 28
Study: 32753620

Group type: EXPERIMENTAL
Intervention: Adipocyte fatty acid binding protein (A-FABP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 0
Study: 32753624

Group type: EXPERIMENTAL
Intervention: Individuals with newly acquired SCI
Number of subjects: 35
Study: 32753849

Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotics
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: Deltoid injection
Number of subjects: 1402

Group type: EXPERIMENTAL
Intervention: 3-monthly dosing
Number of subjects: 1402
Study: 32753875

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with any FDA approved or cleared device
Number of subjects: 689
Study: 32753879

Group type: EXPERIMENTAL
Intervention: pyrotinib (400 mg po qd)
Number of subjects: 1
Study: 32754110

Group type: EXPERIMENTAL
Intervention: Tasimelteon (HETLIOZ®); dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; dosage and duration not available
Number of subjects: 0
Study: 32754307

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 1031
Study: 32755241

Group type: EXPERIMENTAL
Intervention: Pexidartinib (Turalio™) taken orally
Number of subjects: 0
Study: 32755471

Group type: EXPERIMENTAL
Intervention: Chronic oral nitrite therapy (40 mg/3× daily)
Number of subjects: 20
Study: 32755608

Group type: EXPERIMENTAL
Intervention: Pharmacological stimulation targeting β2-adrenergic receptors (β2-AR); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 32755885

Group type: EXPERIMENTAL
Intervention: m2Hear
Number of subjects: 16
Study: 32755884

Group type: EXPERIMENTAL
Intervention: CRM group (smartphone app with wearable activity tracker)
Number of subjects: 73
Study: 32755891

Group type: EXPERIMENTAL
Intervention: Context-adapted CISSS-CA ACE program
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Wiki-suite
Number of subjects: 1635
Study: 32756330

Group type: EXPERIMENTAL
Intervention: Total Sedentary Behavior (SB)
Number of subjects: 9218
Study: 32756876

Group type: EXPERIMENTAL
Intervention: Consecutive vaccination
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Nonconsecutive vaccination
Number of subjects: 1478
Study: 32756938

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 0
Study: 32756984

Group type: EXPERIMENTAL
Intervention: Oral anti-coagulation
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: History of myocardial infarction
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Log-transformed HALT volume
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HALT
Number of subjects: 144
Study: 32757505

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32757642

Group type: EXPERIMENTAL
Intervention: PA pressure-guided therapy
Number of subjects: 1200
Study: 32757661

Group type: EXPERIMENTAL
Intervention: Diamondback 360 Micro Crown Coronary OAS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classic Crown Orbital Atherectomy System (OAS)
Number of subjects: 100
Study: 32757806

Group type: EXPERIMENTAL
Intervention: Reproductive history assessment
Number of subjects: 0
Study: 32757824

Group type: COMPARATOR
Intervention: L-alone (8-session diet and physical activity lifestyle intervention)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: L+Sleep (L-alone plus a behavioral sleep intervention)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (L-alone and L+Sleep)
Number of subjects: 26
Study: 32757853

Group type: EXPERIMENTAL
Intervention: EGFR TKI sequencing
Number of subjects: 0
Study: 32758177

Group type: EXPERIMENTAL
Intervention: Intervention based on the Three-Talk model, including a patient decision aid and decision coaching meetings
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Intervention based on the Three-Talk model
Number of subjects: 349
Study: 32758188

Group type: EXPERIMENTAL
Intervention: Postoperative stereotactic body radiotherapy (SBRT) with a total dose of 36 Gy in 6 fractions over 2 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative stereotactic body radiotherapy (SBRT)
Number of subjects: 90
Study: 32758293

Group type: EXPERIMENTAL
Intervention: Allogeneic expanded umbilical cord-derived mesenchymal stem cells (UC-MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow-derived cells (from previous studies)
Number of subjects: 0
Study: 32758387

Group type: EXPERIMENTAL
Intervention: bioprosthetic autoregulated artificial heart
Number of subjects: 0
Study: 32758434

Group type: EXPERIMENTAL
Intervention: Avadomide (3.0 mg as formulated capsules) plus Obinutuzumab (1000 mg)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Avadomide (various doses) plus Obinutuzumab (1000 mg)
Number of subjects: 73
Study: 32758438

Group type: EXPERIMENTAL
Intervention: Health-care workers screened for IgM and IgG antibodies against SARS-CoV-2
Number of subjects: 28292

Group type: COMPARATOR
Intervention: Health-care workers
Number of subjects: 28292

Group type: EXPERIMENTAL
Intervention: Male health-care workers
Number of subjects: 28292

Group type: EXPERIMENTAL
Intervention: Frontline health-care workers in hospitals
Number of subjects: 28292

Group type: EXPERIMENTAL
Intervention: Health-care workers on dedicated COVID-19 wards
Number of subjects: 28292

Group type: EXPERIMENTAL
Intervention: Seropositive health-care workers
Number of subjects: 28292

Group type: EXPERIMENTAL
Intervention: Participants with loss of taste or smell
Number of subjects: 28292
Study: 32758441

Group type: EXPERIMENTAL
Intervention: Use of facemasks during the COVID-19 pandemic
Number of subjects: 0
Study: 32758563

Group type: EXPERIMENTAL
Intervention: Hanging-induced cardiac arrest
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Survival at hospital discharge
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Favorable neurocognitive outcome
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Factors associated with hospital mortality
Number of subjects: 886
Study: 32759178

Group type: EXPERIMENTAL
Intervention: NEOS score
Number of subjects: 111
Study: 32759248

Group type: EXPERIMENTAL
Intervention: Complement system analysis in ALS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complement system analysis in neurologically healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complement system analysis in non-ALS neurological controls
Number of subjects: 0
Study: 32759249

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 32759265

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 12410

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 12410
Study: 32759300

Group type: EXPERIMENTAL
Intervention: Entecavir cessation based on serum HBV RNA and HBsAg levels
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Serum HBV RNA ≥44.6 U/mL
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combination of HBV RNA undetectability and HBsAg <10 IU/mL
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Off-treatment ALT elevation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HBsAg seroclearance
Number of subjects: 114
Study: 32759360

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 207817

Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 207817
Study: 32760319

Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (walking) for 10 to 30 minutes
Number of subjects: 0
Study: 32760832

Group type: EXPERIMENTAL
Intervention: Lithium (150-300 mg/daily)
Number of subjects: 23
Study: 32761088

Group type: EXPERIMENTAL
Intervention: Severe short-term hypothyroidism
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thyroid hormone supplementation after 20 weeks (median TSH 0.03 mU/L)
Number of subjects: 17
Study: 32761122

Group type: EXPERIMENTAL
Intervention: DAA treatment for replicating HCV infections
Number of subjects: 3715

Group type: EXPERIMENTAL
Intervention: Rescreening for HCV-RNA
Number of subjects: 3715

Group type: EXPERIMENTAL
Intervention: Micro-elimination program
Number of subjects: 3715

Group type: EXPERIMENTAL
Intervention: HCV incidence rate
Number of subjects: 3715
Study: 32761193

Group type: EXPERIMENTAL
Intervention: Composite score incorporating biomarkers (IL-6, IL-10, IL-27, sCD14, interferon-γ, tumor necrosis factor-α, hyaluronic acid, D-dimer, body mass index, hemoglobin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline inflammatory profile and changes in inflammatory networks among biomarkers
Number of subjects: 0
Study: 32761207

Group type: EXPERIMENTAL
Intervention: Serum INSL3 measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Serum testosterone measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Serum INSL3 and testosterone measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Serum LH measurements
Number of subjects: 18
Study: 32761398

Group type: EXPERIMENTAL
Intervention: Segmentation of the fascia lata (FL)
Number of subjects: 73
Study: 32761612

Group type: EXPERIMENTAL
Intervention: Enteric-coated microspheres
Number of subjects: 641

Group type: COMPARATOR
Intervention: Non-enteric coated pancreatic enzyme preparations
Number of subjects: 641
Study: 32761864

Group type: EXPERIMENTAL
Intervention: Cumulative heparin dose
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: ACT measured before sheath removal
Number of subjects: 837